Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Young Potenza’s Promise Attracts Astellas As Potential Buyer

This article was originally published in PharmAsia News

Executive Summary

Astellas has secured an option to acquire the U.S. biotech Potenza as part of a new R&D alliance focusing on immuno-oncology candidates.

You may also be interested in...



Astellas Dips Into Digital Health Via New Venture

New venture DigiTx will give Astellas a leg up in its quest to access novel digital health technologies, in a move unveiled as the Japanese firm reported continued strong growth for top product Xtandi.

Japan Phase III Failure To End Mono Opdivo Hopes In Ovarian Cancer?

While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.

JT Gains World-First Topical JAK Inhibitor Approval

Latest new drug approvals in Japan include the first anywhere for a topical JAK inhibitor and also a marketing clearance for a new contender in the large prostate cancer space.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC088809

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel